| Document and Entity Information | Jun. 06, 2024 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001840574 |
| Document Type | 8-K/A |
| Document Period End Date | Jun. 06, 2024 |
| Entity Registrant Name | Verve Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40489 |
| Entity Tax Identification Number | 82-4800132 |
| Entity Address, Address Line One | 201 Brookline Avenue |
| Entity Address, Address Line Two | Suite 601 |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02215 |
| City Area Code | (617) |
| Local Phone Number | 603-0070 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common stock, $0.001 par value per share |
| Trading Symbol | VERV |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Current Report on Form 8-K/A updates information provided on a Current Report on Form 8-K dated June 7, 2024, relating to disclosures made under Item 5.07, Submission of Matters to a Vote of Security Holders associated with the Verve Therapeutics, Inc. (the “Company”) Annual Meeting of Stockholders held on June 6, 2024 (the “2024 Annual Meeting”). |
